ELVN · Enliven Therapeutics, Inc.
$45.92
-1.06 (-2.25%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$3.28B
Shares
73.27M
Volume · Oct 5
374.68K
Avg daily vol (3M)
1.11M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$46.97
Open$47.38
Day$45.92–47.43
52W close$15.14–61.15
Avg vol 30d1.3M
Short int8.6M · 11.8% float · 9.0d
Short vol74%
Last earningsMay 27, 2026
DataMar 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Apr 4, 2027
Est · unconfirmed
· in 26 wks
filed Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$105.93M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$895.15M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+27.0%
Year over year · more shares
Price change (1Y)
+135.8%
Trailing year
Short interest
11.8%
Latest settlement · 9.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+16%
above
Price vs 50-day avg
−15%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
69%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−21%
trailing
6-month return
+7%
trailing
YTD return
+205%
this year
Relative strength
−5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $55 › 200d $40 — 50d above 200d
Institutional flow
Accumulating
1 of 215 funds reported for Sep 30 · net +32 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.77% of float · ▲ +0.2% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
215 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+16%
Bullish
Price vs 50-day avg
−15%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
69%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $55 › 200d $40 — 50d above 200d
Institutional flow
Accumulating
1 of 215 funds reported for Sep 30 · net +32 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.77% of float · ▲ +0.2% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
215 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $15
Now $47 · 69%
Range high $61
vs 200-day avg +16%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELVN
this stock
Enliven Therapeutics, Inc.
|
$3.28B | +205.0% | — | — | 11.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELVN | +5.0% | -21.3% | +7.2% | +2.5% | +205.0% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +5.2% | -20.8% | -5.0% | +1.6% | +192.1% |